↓ Skip to main content

Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy

Overview of attention for article published in British Journal of Cancer, August 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

news
1 news outlet
twitter
14 tweeters

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
22 Mendeley
Title
Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy
Published in
British Journal of Cancer, August 2017
DOI 10.1038/bjc.2017.253
Pubmed ID
Authors

Rebecca Y Tay, Elizabeth Blackley, Catriona McLean, Maggie Moore, Peter Bergin, Sanjeev Gill, Andrew Haydon

Abstract

Immune-mediated myocarditis is an uncommon adverse effect of immune checkpoint inhibition and is associated with a high rate of mortality. In this reported case, a 64-year-old woman with right temporo-parietal glioblastoma IDH-WT was treated with nivolumab, temozolomide and radiation therapy on a clinical trial. She developed malignant arrhythmias secondary to histologically confirmed severe immune-mediated myocarditis. She was treated with equine anti-thymocyte globulin (ATGAM) due to development of malignant arrhythmias refractory to high-dose corticosteroids. This report describes the only case of immune-mediated myocarditis treated with ATGAM resulting in a favourable outcome. Use of ATGAM should be considered in cases of steroid-refractory immune-mediated myocarditis and administered in close consultation with a cardiac transplant team experienced in the use of this agent.British Journal of Cancer advance online publication: 10 August 2017; doi:10.1038/bjc.2017.253 www.bjcancer.com.

Twitter Demographics

The data shown below were collected from the profiles of 14 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 22 100%

Demographic breakdown

Readers by professional status Count As %
Other 6 27%
Student > Ph. D. Student 3 14%
Professor 2 9%
Researcher 2 9%
Student > Master 2 9%
Other 1 5%
Unknown 6 27%
Readers by discipline Count As %
Medicine and Dentistry 14 64%
Engineering 1 5%
Unknown 7 32%

Attention Score in Context

This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 October 2017.
All research outputs
#884,910
of 13,115,954 outputs
Outputs from British Journal of Cancer
#533
of 8,036 outputs
Outputs of similar age
#31,332
of 265,917 outputs
Outputs of similar age from British Journal of Cancer
#15
of 118 outputs
Altmetric has tracked 13,115,954 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,036 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 265,917 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 118 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.